Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01316666 · ClinicalTrials.gov registry record
Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 50
- Enrollment target
NCT01316666 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 50 participants.
The verdict
NCT01316666 has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
The autonomic or automatic nervous system helps control blood pressure. Diseases of the autonomic nervous system may result in a drop in blood pressure on standing in many cases leading to fainting. Diseases that affect the autonomic nervous system include pure autonomic failure, multiple system atrophy and Parkinson's disease, and can present with very similar symptoms and it is sometimes difficult to determine an exact diagnosis. The purpose of the study is to find out if the blood pressure response from taking a single dose of the medication atomoxetine can help in the diagnosis of these diseases.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2011-03 |
| Est. Completion | 2016-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01316666
The ClinicalTrials.gov registry entry for NCT01316666 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01316666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01316666 about?
NCT01316666 is a clinical study titled "Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension". The autonomic or automatic nervous system helps control blood pressure. Diseases of the autonomic nervous system may result in a drop in blood pressure on standing in many cases leading to fainting. Diseases that affect the autonomic nervous system include pure autonomic failure, multiple system atr...
What is the current status of trial NCT01316666?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2011-03. Estimated completion is 2016-12.
Who is sponsoring clinical trial NCT01316666?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.